Literature DB >> 10724127

The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.

P E Keck1, S M Strakowski, S L McElroy.   

Abstract

Depressive symptoms and syndromal depression commonly occur in patients with schizophrenia. Schizophrenia is also associated with aggression directed at self and others. For this article, the available literature regarding the efficacy of clozapine, risperidone, olanzapine, quetiapine, and ziprasidone in the treatment of depression, hostility, and suicidality in patients with schizophrenia was reviewed. These studies suggest that atypical antipsychotics may exert therapeutic effects on depression and hostility as well as psychosis and that clozapine and olanzapine may reduce suicidality in patients with schizophrenia. These therapeutic actions appear to represent additional advantages of atypical antipsychotics compared with standard agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10724127

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Elucidating biological risk factors in suicide: role of protein kinase A.

Authors:  Yogesh Dwivedi; Ghanshyam N Pandey
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-09-09       Impact factor: 5.067

Review 3.  Behavioral and pharmacogenetics of aggressive behavior.

Authors:  Aki Takahashi; Isabel M Quadros; Rosa M M de Almeida; Klaus A Miczek
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 4.  Brain serotonin receptors and transporters: initiation vs. termination of escalated aggression.

Authors:  Aki Takahashi; Isabel M Quadros; Rosa M M de Almeida; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2010-09-03       Impact factor: 4.530

Review 5.  The effectiveness of atypical antipsychotic medications in depressive disorders.

Authors:  Waguih William Ishak; Mark H Rapaport; Jennifer G Gotto
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

Review 6.  Postpsychotic depression in schizophrenia patients.

Authors:  Christian G Kohler; Elise A Lallart
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

7.  Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Joseph McEvoy; Marvin Swartz; Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

8.  Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.

Authors:  Y Barak; I Mirecki; H Y Knobler; Z Natan; D Aizenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-02-04       Impact factor: 4.530

Review 9.  Quetiapine. A review of its use in the management of schizophrenia.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.

Authors:  Chrissoula Stavrakaki; Ruxandra Antochi; Patricia C Emery
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.